Thermo Fishr Sci Stock Price, News & Analysis

Thermo Fisher Scientific (NYSE:TMO) confirmed that its TaqPath COVID-19 tests accurately detect the Omicron variant, ensuring reliable results despite the variant's mutations. The tests, which target three gene regions, remain unaffected in accuracy due to the unaffected orf1a/b and N gene targets. New TaqPath COVID-19 2.0 tests utilize eight gene targets to detect SARS-CoV-2 effectively. This capability is crucial for tracking the Omicron variant's spread and supporting global pandemic response efforts.

Thermo Fisher Scientific (NYSE:TMO) announced its plan to redeem Senior Notes totaling approximately $2.2 billion on December 3, 2021. The redemption includes $1.1 billion of 4.133% Senior Notes due 2025 and $1.1 billion of 4.497% Senior Notes due 2030. Investors will receive the greater of the principal amount or the present value of remaining scheduled payments, plus accrued interest. The company will fund the redemption using cash on hand. This move highlights the firm's commitment to managing its debt effectively.

Thermo Fisher Scientific (NYSE: TMO) has priced a €2.8 billion offering of euro-denominated senior notes, which includes €1.7 billion in floating rate notes, €550 million in 0.000% senior notes due 2023, and €550 million in sustainability notes due 2025. The offering is expected to close around November 18, 2021. Proceeds will be used to support the acquisition of PPD, Inc. and for general corporate purposes. The sustainability notes aim to fund eligible green projects. The offering complies with SEC regulations and is targeted at professional investors.

Thermo Fisher Scientific (NYSE: TMO) declared a quarterly cash dividend of $0.26 per common share, payable on January 14, 2022, to shareholders of record by December 15, 2021. The company, a leader in serving science with around $35 billion in annual revenue, aims to enhance health, cleanliness, and safety globally. They support life sciences research, diagnostics, and laboratory productivity through their renowned brands, including Thermo Scientific and Applied Biosystems.

Thermo Fisher Scientific (NYSE: TMO) has unveiled a suite of advanced mass spectrometry instruments and software at the ASMS 2021 Conference in Philadelphia. The new offerings, including the Orbitrap Exploris MX, aim to streamline biopharmaceutical development and quality control processes. Notable enhancements include the MAM 2.0 workflow, which integrates multiple assays into one analysis, and innovative software solutions like Proteome Discoverer 3.0 and Compound Discoverer 3.3, leveraging AI for improved data analysis. Thermo Fisher reported annual revenue of approximately $35 billion.

Thermo Fisher Scientific (NYSE: TMO) reported a 9% increase in third-quarter revenue to $9.33 billion, with GAAP diluted EPS at $4.79 and adjusted EPS rising 2% to $5.76. COVID-19 response revenue was $2.05 billion. The company raised its 2021 revenue guidance to $37.1 billion, projecting 15% growth, and adjusted EPS guidance to $23.37, indicating a 20% year-over-year growth. Major innovations included new products in oncology and biopharma, alongside expanding capacities in North Carolina and South Korea to support vaccine production.

Thermo Fisher Scientific (TMO) released its 2020 Corporate Social Responsibility (CSR) report, highlighting significant commitments to environmental, social, and governance (ESG) efforts. Key achievements include producing over 700 million PCR-based COVID-19 tests and investing $1.3 billion in diverse-owned businesses. The report also showcases initiatives for colleague support, with 40% of leadership hires being women, a $30 million investment in STEM education, and a $25 million COVID-19 testing program for historically black colleges. The company is on track to achieve a 30% reduction in greenhouse gas emissions by 2030.

Thermo Fisher Scientific (NYSE: TMO) has priced a $5.85 billion offering of senior notes, which includes $1 billion of 18-month floating rate notes, $1.35 billion of 0.797% senior notes, and $2.5 billion of 1.215% senior notes due in 2024. The offering is set to close on or about October 22, 2021. Proceeds will primarily finance the acquisition of PPD, Inc., with potential uses for general corporate purposes. Interest on floating rate notes will be paid quarterly, while fixed rate notes will pay semi-annually.

Thermo Fisher Scientific (NYSE: TMO) announced its intention to offer USD-denominated senior notes to help fund its proposed acquisition of PPD, Inc. The notes will also support general corporate purposes, such as debt refinancing and working capital. The offering is led by joint book-running managers including Barclays, Morgan Stanley, and BofA Securities. This action follows an effective registration statement filed with the SEC. Investors should note the potential risks associated with capital market conditions and the acquisition timeline.